TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30421023

Group type: EXPERIMENTAL
Intervention: Discontinuation of imatinib therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Dasatinib treatment after molecular recurrence
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Time from diagnosis to discontinuation of imatinib therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Duration of imatinib therapy
Number of subjects: 99
Study: 29499839

Group type: EXPERIMENTAL
Intervention: Virtual Traveller intervention (10-min physically active Virtual Field Trips three times a week for six weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Virtual Traveller intervention
Number of subjects: 5
Study: 27212183

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 70
Study: 24610183

Group type: EXPERIMENTAL
Intervention: Minimum AVS content
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Intermediate AVS content
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Maximum AVS content
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Standard AVS content
Number of subjects: 272

Group type: COMPARATOR
Intervention: All groups (minimum, intermediate, maximum, standard)
Number of subjects: 272
Study: 22282101

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.75 mg estradiol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.375 mg estradiol
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.27 mg estradiol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 21050549

Group type: EXPERIMENTAL
Intervention: IVIG (0.2g/kg intravenously before conception, continued every 4 weeks until the 20th gestational week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Traditional Chinese medicine or/and progesterone)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 17698724

Group type: EXPERIMENTAL
Intervention: EST (established recommendations)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: EST+DASH (established recommendations plus DASH dietary pattern)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Advice only control group
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Both EST and EST+DASH
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure, lipids, and homeostasis model assessment
Number of subjects: 796
Study: 15703502

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin 10-20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin 20-40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Branded simvastatin 10-80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic simvastatin 40-80 mg
Number of subjects: 0
Study: 12213159

Group type: EXPERIMENTAL
Intervention: Daunorubicin (5 microg) intravitreal injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no daunorubicin)
Number of subjects: 30
Study: 10458045

Group type: EXPERIMENTAL
Intervention: Social phobia patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panic disorder patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 7608243

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg intravenously every six hours for four doses)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (saline solution, intravenously every six hours for four doses)
Number of subjects: 59
Study: 1695308

Group type: EXPERIMENTAL
Intervention: Isradipine (mean dose of 3.6 mg daily)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Nifedipine (mean dose of 50 mg daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 656265

Group type: EXPERIMENTAL
Intervention: Salivary oxprenolol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Salivary metoprolol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Plasma oxprenolol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Plasma metoprolol
Number of subjects: 2
Study: 30971174

Group type: EXPERIMENTAL
Intervention: N-SORB (1 mL, twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 27230030

Group type: EXPERIMENTAL
Intervention: Post-Conditioning (PostCond)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 25347938

Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin once daily for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin
Number of subjects: 0
Study: 23873790

Group type: EXPERIMENTAL
Intervention: Mindfulness-based art therapy (MBAT)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard educational support
Number of subjects: 191
Study: 22142348

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCTZ 150/12.5 mg
Number of subjects: 860

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 860
Study: 19197536

Group type: EXPERIMENTAL
Intervention: Oral liarozole (75 or 150 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy control group (no treatment)
Number of subjects: 11
Study: 16492838

Group type: EXPERIMENTAL
Intervention: Amantadine sulfate 100 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14601047

Group type: EXPERIMENTAL
Intervention: Proline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proline with ASC
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 10789532

Group type: EXPERIMENTAL
Intervention: Intensive dynamic psychotherapy (IDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial therapists
Number of subjects: 0
Study: 8673810

Group type: EXPERIMENTAL
Intervention: VIDAS Lyme Screen II (LYT II)‐bioMérieux
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lyme Borreliosis‐Dako
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Borrelia Recombinant‐Biomedica
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neuroborreliosis patients
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: bioMérieux test
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dako‐IgG
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Biomedica‐IgG
Number of subjects: 112
Study: 1365489

Group type: EXPERIMENTAL
Intervention: Droxicam (20mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin (75mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study: 6614773

Group type: EXPERIMENTAL
Intervention: High negative pressure drain
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low negative pressure drain
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simple tube drain
Number of subjects: 120
Study: 31776742

Group type: EXPERIMENTAL
Intervention: Sequential fluoroscopy guidance
Number of subjects: 385

Group type: COMPARATOR
Intervention: Spiral guidance
Number of subjects: 385
Study: 30679232

Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 2

Group type: COMPARATOR
Intervention: HMG-CoA reductase inhibitor or blocking antibody against proprotein convertase subtilisin/kexin type 9
Number of subjects: 2
Study: 28199463

Group type: EXPERIMENTAL
Intervention: AFL‐PDT (1 session)
Number of subjects: 45

Group type: COMPARATOR
Intervention: MAL‐PDT (2 sessions)
Number of subjects: 45
Study: 24978160

Group type: EXPERIMENTAL
Intervention: Peer support intervention (135 randomized)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 266
Study: 23713297

Group type: EXPERIMENTAL
Intervention: Warm needling therapy combined with rehabilitation training
Number of subjects: 88

Group type: COMPARATOR
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 88
Study: 21402326

Group type: EXPERIMENTAL
Intervention: Manual chest wall compression with vibrations and increased pressure support ventilation by 10 cm H(2)O
Number of subjects: 66

Group type: COMPARATOR
Intervention: Manual chest wall compression with vibrations (no adjustment of ventilator settings)
Number of subjects: 66
Study: 20126902

Group type: EXPERIMENTAL
Intervention: TR+ (non-surgical periodontal treatment)
Number of subjects: 75

Group type: COMPARATOR
Intervention: TR- (no treatment for periodontal disease)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total prosthesis (TP)
Number of subjects: 75
Study: 17003306

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO group; 45 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Plc group)
Number of subjects: 20
Study: 15515037

Group type: EXPERIMENTAL
Intervention: 20 microT magnetic field exposure
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 400 microT magnetic field exposure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Condition out of the helmet (control)
Number of subjects: 32
Study: 11115695

Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Havrix
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Havrix-Vaqta
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vaqta-Havrix
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 201
Study: 9929284

Group type: EXPERIMENTAL
Intervention: Computerized reminder system
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Historic controls
Number of subjects: 2013
Study: 7770136

Group type: EXPERIMENTAL
Intervention: Alkalinizing therapy (group I)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: L-carnitine (group II)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline solution (group III)
Number of subjects: 65
Study: 3291623

Group type: EXPERIMENTAL
Intervention: Nix (permethrin 1% creme rinse)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Rid
Number of subjects: 435
Study: 31585725

Group type: EXPERIMENTAL
Intervention: Vi-DT (25 µg)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 285
Study: 30880698

Group type: EXPERIMENTAL
Intervention: Dual therapy with lopinavir/ritonavir plus lamivudine (DT group)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Chinese first-line triple-therapy regimen (TT group)
Number of subjects: 198
Study: 28882910

Group type: EXPERIMENTAL
Intervention: Locally produced lipid-based nutrient supplement (LNS)
Number of subjects: 100
Study: 26882609

Group type: EXPERIMENTAL
Intervention: Acupuncture group A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture group B
Number of subjects: 120

Group type: COMPARATOR
Intervention: Common treatment group
Number of subjects: 120
Study: 24127770

Group type: EXPERIMENTAL
Intervention: Internal jugular catheter
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Femoral catheter
Number of subjects: 2128
Study: 21438796

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/day
Number of subjects: 345
Study: 19032135

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (twice daily for 7 days)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (3 times daily for 7 days)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (for patients with P. aeruginosa)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with P. aeruginosa)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (for patients with S. aureus)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with S. aureus)
Number of subjects: 630
Study: 16802269

Group type: EXPERIMENTAL
Intervention: Olympus HX‐200L‐135
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wilson‐Cook Tri‐Clip
Number of subjects: 80
Study: 11958590

Group type: EXPERIMENTAL
Intervention: Cervical concentrations of interleukin‐10 (IL‐10)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical concentrations of interleukin‐12 (IL‐12)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ratio of IL‐12 to IL‐10
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical concentrations of IL‐10 among nonsmokers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical concentrations of IL‐10 during day 18‐27 of menstrual cycle
Number of subjects: 70
Study: 10191325

Group type: EXPERIMENTAL
Intervention: Selective color constancy task
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Color discrimination or higher-level visual tasks
Number of subjects: 27
Study: 8672320

Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurement using the reverse Fick principle (cVO2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gas exchange method (mVO2)
Number of subjects: 9
Study: 2179638

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytosine arabinoside
Number of subjects: 200

Group type: COMPARATOR
Intervention: Daunorubicin-based regimen
Number of subjects: 200
Study: 383274

Group type: EXPERIMENTAL
Intervention: 1-phenylalanine mustard (L-PAM)
Number of subjects: 0
Study: 6861862

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 60 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30536047

Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia and femoral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Femoral nerve block alone
Number of subjects: 40
Study: 29522223

Group type: EXPERIMENTAL
Intervention: toriCAM application
Number of subjects: 22

Group type: COMPARATOR
Intervention: freehand marking method
Number of subjects: 22

Group type: COMPARATOR
Intervention: slit-lamp marking method
Number of subjects: 22
Study: 27068628

Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII) scores (Quartile 4)
Number of subjects: 7743

Group type: COMPARATOR
Intervention: Lower Dietary Inflammatory Index (DII) scores (Quartile 1)
Number of subjects: 7743
Study: 24612093

Group type: EXPERIMENTAL
Intervention: 10-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 10 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 12-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 12 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 14 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220
Study: 22506674

Group type: EXPERIMENTAL
Intervention: Physical Coordination Training (PCT)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Training (CBTr)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 294
Study: 19606244

Group type: EXPERIMENTAL
Intervention: 0.1 N hydrochloric acid (HCl) infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 29
Study: 17621237

Group type: EXPERIMENTAL
Intervention: Darunavir (TMC114) with low-dose ritonavir (600/100 mg twice daily)
Number of subjects: 327
Study: 15590214

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen combined with 5 mg medroxyprogesterone acetate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 50 mcg transdermal estrogen alone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 12381833

Group type: EXPERIMENTAL
Intervention: Resistance training for the index finger abductors (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study: 10022995

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (70 mg/m2) and intravenous carboplatin (target AUCs of 4, 5, 6, and 7) with G-CSF (50 microgram/m2 from day 7 to 16)
Number of subjects: 25
Study: 10159752

Group type: EXPERIMENTAL
Intervention: 0.010" balloon PTCA system
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.014" balloon PTCA system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inexperienced fellow as primary operator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Experienced attending physician as primary operator
Number of subjects: 50
Study: 2283650

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 378316

Group type: EXPERIMENTAL
Intervention: 2/0 Dexon suture subcuticularly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other suture methods (not specified)
Number of subjects: 0
Study: 31856601

Group type: EXPERIMENTAL
Intervention: Challenges and barriers identified through a three-round modified Delphi survey with international trials researchers.
Number of subjects: 0
Study: 29541862

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate nasal spray (0.1 mg/ml, 10 μg/spray) once daily for 10 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate nasal spray
Number of subjects: 110
Study: 29757889

Group type: EXPERIMENTAL
Intervention: 3-signal T-cell activation (T-cell receptor activation, CD137/4-1BB stimulation, interleukin-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-signal T-cell activation
Number of subjects: 0
Study: 27358142

Group type: EXPERIMENTAL
Intervention: Lactulose oral solution, 15 ml once a day, maintenance dose of 515 ml/time as needed, treatment lasted for six weeks.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (blank controls)
Number of subjects: 211
Study: 24768330

Group type: EXPERIMENTAL
Intervention: Surgery for residual disease (Arm A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Imatinib mesylate (IM) treatment alone (Arm B)
Number of subjects: 41
Study: 21866055

Group type: EXPERIMENTAL
Intervention: Maternal height (r = 0.324 at 6 months)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Maternal height (r = 0.335 at 12 months)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 412
Study: 20558081

Group type: EXPERIMENTAL
Intervention: Method of managing gastric residual volume (returning vs discarding)
Number of subjects: 0
Study: 17959975

Group type: EXPERIMENTAL
Intervention: Forced air-warming
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (identical cover with forced air-warming unit switched off)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 15805381

Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 252

Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 252
Study: 12356634

Group type: EXPERIMENTAL
Intervention: Atrial flutter termination
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pacing at cycle lengths of 750 to 250 ms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium administration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postpacing pause
Number of subjects: 35

Group type: COMPARATOR
Intervention: Paroxysmal AFL group (control)
Number of subjects: 35
Study: 10096462

Group type: EXPERIMENTAL
Intervention: Add-back hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose progestogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose progestogen plus cyclical etidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard and low-dose HRT add-back
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose and standard-dose add-back HRT
Number of subjects: 0
Study: 7762716

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 3348

Group type: EXPERIMENTAL
Intervention: Video plus interactive group discussion
Number of subjects: 3348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3348
Study: 1980611

Group type: EXPERIMENTAL
Intervention: Anticholinergic medication
Number of subjects: 10
Study: 7000239

Group type: EXPERIMENTAL
Intervention: Sauna (twice for 25 minutes at 85 degrees C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Room temperature (control)
Number of subjects: 8
Study: 29973367

Group type: EXPERIMENTAL
Intervention: Known or newly diagnosed diabetes
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Blood glucose level ≥200 mg/dL in participants with known diabetes
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Ophthalmological examination for diabetic retinopathy (DR)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Prevalence of diabetic retinopathy (DR) and/or maculopathy
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Age-adjusted and sex-adjusted prevalence of diabetes
Number of subjects: 1192
Study: 30098071

Group type: EXPERIMENTAL
Intervention: Once-daily, prolonged-release tacrolimus (PR-T)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Twice-daily, immediate-release tacrolimus (IR-T)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both PR-T and IR-T
Number of subjects: 100
Study: 27559727

Group type: EXPERIMENTAL
Intervention: MSP‐α plasma level in women with preeclampsia (PE)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MSP‐α plasma level in women without severe features of PE
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MSP staining in placentas of women with PE
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MSP staining in placentas of women without severe features of PE
Number of subjects: 124
Study: 24631433

Group type: EXPERIMENTAL
Intervention: Burch or fascial sling surgery
Number of subjects: 491